The latest Market Talks covering ESG Impact Investing. Published exclusively on Dow Jones Newswires at 10:00 ET and 17:00 ET.

0740 ET - Argenx's positive results for a midstage clinical trial in celiac disease vindicates its CEO change earlier this year, Bernstein analysts say in a research note. The Amsterdam-based biotech company said a drug candidate it acquired through its Forte Biosciences deal, FB102, hit the goal in a study, reinforcing the potential of a medicine being tested for two diseases with little or no existing nonsystemic drug treatment options, the analysts say. "A key rationale for the CEO transition was to diversify the organic pipeline with external innovation," the analysts add. Argenx separately said it would discontinue a trial for its main drug Vyvgart in Sjogren's disease. This should come as little surprise given that Sjogren's is a heterogeneous disease that has become a research-and-development "graveyard" for the industry, according to Bernstein. Shares fall 16%. (adria.calatayud@wsj.com)

1330 ET - Ariel Investments doesn't necessarily want Mattel to sell itself. The asset-management firm, which has a 5.4% stake in the toymaker, says Barbie-doll maker should retain an independent financial advisory firm to explore various strategic alternatives, including a divestiture of significant assets, a merger or an outright sale. "We think (the board) will do the right thing for shareholders," Ariel Co-CEO John Rogers says in an interview with CNBC. "The leaders there have shown a history of doing the right thing." (connor.hart@wsj.com)

1323 ET - Ariel Investments Co-CEO John Rogers says Ynon Kreiz's departure from Mattel played "a big part" in the asset-management firm's decision to call for the toymaker to explore strategic alternatives. "Ynon had done a great job restructuring the business," Rogers says in an interview with CNBC. "He had a plan in place." That won't necessarily be the case under Roger Lynch, who was tapped to succeed Kreiz as Mattel's next CEO last week. "We don't want to start over again," Rogers says. He adds that Ariel is becoming impatient, as Mattel's shares remain significantly undervalued with its current structure as a public company.